At the Standalone during the January to March 2025 quarter, the Sudarshan Pharma Industries net profit at ₹9.95 crore also saw a sharp rise The net profit for the quarter reported buy the ...

Explore Ascendis Pharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ASND. Why Is BioMarin Stock Trading Higher On Thursday? BioMarin exceeded Q4 ...

Shelter Pharma, operating in the Pharmaceuticals sector and classified as a Smallcap on the BSE, currently has its share price at ₹38.1. The stock has experienced fluctuations today, with a low ...

UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in ...

MPS Pharma, operating in the Pharmaceuticals sector and classified as a Smallcap on the BSE, currently has its share price at ₹2.74. The stock has experienced fluctuations today, with a low of ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on aTyr Pharma (NASDAQ ... analysts are notably bullish on the stock, with price targets ranging from $9 to $35, significantly above ...

Nomura India has reaffirmed its 'Buy' rating on Cipla Ltd with a target price of Rs 1,780 by March ... Disclaimer: Business Today provides stock market news for informational purposes only and ...

Following this update, Gland Pharma share price traded marginally higher in Wednesday's trading session. The stock rose 0.8% to the day's high of ₹1439. With today's gains, the stock has risen ...

Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space. A New Pope Has Been Elected How to hard boil eggs without using water Panama president ...

Vincerx Pharma, Inc. announced that it intends to voluntarily delist its common stock from Nasdaq after receiving a notice of non-compliance due to the stock's closing bid price falling below the ...

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and AstraZeneca’s AZN blockbuster cancer drugs, Imfinzi and Daiichi-Sankyo ...